Zimmerman Program on the Biology of VWD

Overview

About this study

The purpose of this study is to study the relationship between genetic defects of the von Willebrand Factor (VWF) or related genes and the clinical impact on the diagnosis and management of their von Willebrand Disease (VWD) bleeding disorder. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients age 2 years and older.
  • Patients who are either being evaluated for or have been identified as having VWD.
  • Consent will obtained from one parent and assent from children ≥ 7 years of age.  To confirm assent, children 7 to 13 years of age will sign an assent form and children 14 to 17 years of age will co-sign the consent form.
  • If a patient who is already enrolled in the study comes for a follow-up visit and they have turned 18 years old, they will be re-consented. 

Exclusion Criteria:

  • Patients not identified as having VWD.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rajiv Pruthi, M.B.B.S.

Contact us for the latest status

Contact information:

Tiffany Plowman

(507) 284-5095

Plowman.Tiffany@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20516999

Mayo Clinic Footer